The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Bayer
Molecular characterization and management of secondary resistance to serial TRK inhibitors.
 
Michael Nathenson
No Relationships to Disclose
 
Matthew Louis Hemming
No Relationships to Disclose
 
Karan Malik
No Relationships to Disclose
 
Jia-Ren Lin
No Relationships to Disclose
 
Sandro Santagata
No Relationships to Disclose
 
Ziming Du
No Relationships to Disclose
 
Adrian Marino-Enriquez
No Relationships to Disclose
 
Timothy J Hagan
No Relationships to Disclose
 
Otari Chipashvili
No Relationships to Disclose
 
Katherine Anne Thornton
Consulting or Advisory Role - Agios; Lilly; More Health; Novartis
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Novartis
 
Chandrajit P. Raut
Honoraria - Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Barrett H. Childs
No Relationships to Disclose
 
Monica M. Bertagnolli
Leadership - Leap Therapeutics
Consulting or Advisory Role - Syntalogic Pharmaceuticals; Syntimmune
Research Funding - Abbvie (Inst); Agenus (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer Health (Inst); Breast Cancer Research Foundation (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Complion (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GHI Pharma (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Leidos (Inst); Leidos (Inst); Lexicon (Inst); Lilly (Inst); Massachusetts General Hospital (Inst); Matrex (Inst); Mayo Clinic (Inst); Merck (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Patient-Centered Outcomes Research Institute (PCORI) (Inst); Pfizer (Inst); Pharmacyclics (Inst); Robert Wood Johnson Foundation (Inst); Sagerock Advisors (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Teva (Inst)
 
Ewa Sicinska
No Relationships to Disclose
 
Nora Ku
Employment - Loxo
Honoraria - Amgen (I); AstraZeneca (I); bioTheranostics (I); Cascadian Therapeutics (I); Genentech/Roche (I); Macrogenics (I); Novartis (I); Peregrine Pharmaceuticals (I); Pfizer (I); Pierian Biosciences (I)
Travel, Accommodations, Expenses - Amgen (I); AstraZeneca (I); bioTheranostics (I); Genentech/Roche (I); Macrogenics (I); Novartis (I); Peregrine Pharmaceuticals (I); Pfizer (I); Pierian Biosciences (I)
 
George D. Demetri
Leadership - Blueprint Medicines; Merrimack
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; Erasca, Inc; G1 Therapeutics; Merrimack
Consulting or Advisory Role - Adaptimmune; Bayer; Blueprint Medicines; Caris Life Sciences; Daiichi Sankyo; EMD Serono; G1 Therapeutics; ICON Clinical Research; Ignyta; Janssen Oncology; Loxo; Medscape; Mirati Therapeutics; MJH Associates; Novartis; Pfizer; PharmaMar; Polaris; Roche/Genentech; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - AbbVie (Inst); Abbvie (Inst); Adaptimmune (Inst); Bayer (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Janssen Oncology (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent on use of imatinib for GIST, receive minor royalty payment from Dana-Farber after license between Dana-Farber and Novartis